Cardiogenic shock inotrop choice
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have sufficient content from multiple major textbooks. Let me compile the answer.
Inotrope Choice in Cardiogenic Shock
Overview
Cardiogenic shock (CS) is a low-output state causing life-threatening end-organ hypoperfusion — typically defined as SBP <90 mmHg unresponsive to volume, accompanied by elevated lactate (>2 mmol/L). In-hospital mortality is 40–60%. Vasoactive drug selection depends on the hemodynamic profile and blood pressure at presentation.
Drug-by-Drug Summary
| Drug | Mechanism | Dose | Key Points |
|---|---|---|---|
| Dobutamine | β1/β2 agonist (± α) | 2–20 µg/kg/min | First-line inotrope if SBP ≥90 mmHg |
| Norepinephrine | α1 >> β1 | 2 µg/min, titrate | Preferred vasopressor if SBP <70 mmHg; combine with dobutamine |
| Dopamine | β1 (3–10 µg/kg/min) → α1 (>10 µg/kg/min) | 3–50 µg/kg/min | Alternative but more arrhythmogenic; increases LVEDP |
| Epinephrine | β1, β2, α1 | 0.1–0.5 µg/kg/min | Second-tier; causes acidosis, tachycardia, dysrhythmias |
| Milrinone | PDE-3 inhibitor (↑ cAMP) | 0.5 µg/kg/min | Use if on β-blocker or dobutamine-refractory; vasodilates (↓ BP) |
Decision Framework
SBP ≥ 90 mmHg → Dobutamine first-line
- Most widely used inotrope in Europe and the USA
- Low doses (1–2 µg/kg/min) improve renal perfusion; higher doses (5–10 µg/kg/min) for profound hypoperfusion
- Watch for tachyphylaxis after 24–48 h (receptor desensitization)
- Avoid if patient is on a β-blocker — use milrinone instead (no competitive antagonism)
SBP < 70 mmHg → Norepinephrine preferred over dobutamine
- Norepinephrine + dobutamine combination has a more profound vasoconstrictive effect than dopamine + dobutamine
- Dobutamine's vasodilatory effect (β2) is hazardous when BP is critically low
β-Blocker use → Milrinone
- β-blockers blunt dobutamine's effect; doses of 10–20 µg/kg/min may be needed, increasing toxicity risk
- Milrinone acts downstream of β-receptors (PDE-3 inhibition) — unaffected by β-blockade
- Caveat: milrinone is renally cleared — use cautiously in significant renal dysfunction
Epinephrine — second-tier
- Potent inotrope + vasopressor, but increases systemic acidosis, tachycardia, and arrhythmias compared to norepinephrine + dobutamine combination
- Reserve for refractory cases
Dopamine — generally inferior
- Inotropic at 3–10 µg/kg/min; vasoconstrictive at >10 µg/kg/min
- Increases LVEDP and heart rate — worsens myocardial oxygen demand
- Greater arrhythmia risk; epinephrine and the NE+dobutamine combination are preferred
Key Caveats
- Pure vasoconstrictors (e.g. phenylephrine) are contraindicated — increase afterload without augmenting contractility
- All inotropes increase AV node conduction → risk of rapid ventricular response in atrial fibrillation
- Inotropes are a bridge, not definitive therapy — persistent CS despite vasoactives warrants mechanical circulatory support (IABP, Impella, ECMO)
- If shock persists or escalates, early escalation to MCS is preferred over stacking vasopressors
Sources: Harrison's Principles of Internal Medicine 22e, p. 2368–2372; Tintinalli's Emergency Medicine, p. 397; Braunwald's Heart Disease, pp. 119–120
This is a shared conversation. Sign in to Orris to start your own chat.